• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI Executive AssistantNEW
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI Executive AssistantNEW
  • Settings
  • RSS Feeds
PublishGo to AppAI Helper
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI employees for your businessNEW
    Legal
    Terms of usePrivacy policyCookie policy

    PharmaLogic Announces Appointment of Etienne Montagut as President and Chief Executive Officer

    6/2/25 8:00:00 AM ET
    $GEHC
    $LNTH
    Medical Electronics
    Health Care
    Biotechnology: In Vitro & In Vivo Diagnostic Substances
    Health Care
    Get the next $GEHC alert in real time by email

    BOCA RATON, Fla., June 2, 2025 /PRNewswire/ -- PharmaLogic Holdings Corp. ("PharmaLogic" or "the Company"), a leading contract development and manufacturing organization (CDMO) specialized in radiopharmaceuticals, today announces the Company has appointed Etienne Montagut, currently serving as President, to the position of President and Chief Executive Officer, effective as of 1 June 2025.

    Logo for PharmaLogic Holdings Corporation.

    Mr. Montagut brings over 25 years of senior leadership experience in the pharmaceutical sector, with a solid track record of driving growth and executing strategic transformation across global markets. Prior to joining PharmaLogic one year ago, he held executive positions at Lantheus (NASDAQ:LNTH), GE HealthCare (NASDAQ:GEHC) and Ipsen (EURONEXT: IPN).

    Steve Chilinski, who has led the company through 13 years of exceptional growth, retired as Chief Executive Officer on June 1, 2025, and will assume the role of Executive Chairman of the Board.

    "I'm grateful to Steve and the Board for their trust and their confidence in PharmaLogic's future," said Etienne Montagut. "The company has experienced great success, and I'm very excited about our next chapter. PharmaLogic has talent, culture, technology, and resources to lead the future of radiopharmaceuticals and improve global patient access to novel diagnostics and therapies."

    About PharmaLogic Holdings Corp.

    PharmaLogic is a leading global contract development and manufacturing organization (CDMO) specialized in diagnostic and therapeutic radiopharmaceuticals. With decades of industry expertise and a robust network of more than 45 facilities across the U.S., Puerto Rico, Canada, and Norway, PharmaLogic delivers comprehensive solutions spanning development, manufacturing, and distribution of both clinical and commercial-stage radiopharmaceutical products, all in accordance with the highest quality and regulatory standards.

    Our rapidly expanding diagnostics business leverages advanced technologies to enhance patient access to novel diagnostics in oncology, cardiology, and Alzheimer's disease. In the therapeutic segment, PharmaLogic is the world's only cGMP-compliant CDMO currently manufacturing and distributing a commercial radiopharmaceutical therapeutic across more than 30 countries.

    PharmaLogic is dedicated to enabling global patient access to radiopharmaceuticals through strategic development partnerships with industry innovators, advancing the future of the field and supporting our partners throughout the product lifecycle. For more information, visit radiopharmacy.com and follow us on LinkedIn.

     

    Cision View original content to download multimedia:https://www.prnewswire.com/news-releases/pharmalogic-announces-appointment-of-etienne-montagut-as-president-and-chief-executive-officer-302470235.html

    SOURCE PharmaLogic Holdings Corp

    Get the next $GEHC alert in real time by email

    Crush Q3 2025 with the Best AI Executive Assistant

    Stay ahead of the competition with Tailforce.ai - your AI-powered business intelligence partner.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Tailforce.ai

    Recent Analyst Ratings for
    $GEHC
    $LNTH

    CompanyDatePrice TargetRatingAnalyst
    GE HealthCare Technologies Inc.
    $GEHC
    5/5/2025$73.00Sell → Neutral
    UBS
    GE HealthCare Technologies Inc.
    $GEHC
    3/11/2025$85.00 → $100.00Neutral → Buy
    Goldman
    GE HealthCare Technologies Inc.
    $GEHC
    1/8/2025$95.00 → $103.00Hold → Buy
    Jefferies
    Lantheus Holdings Inc.
    $LNTH
    12/18/2024$143.00Buy
    Goldman
    GE HealthCare Technologies Inc.
    $GEHC
    9/26/2024$84.00 → $74.00Neutral → Sell
    UBS
    GE HealthCare Technologies Inc.
    $GEHC
    9/18/2024$100.00Neutral → Buy
    BTIG Research
    GE HealthCare Technologies Inc.
    $GEHC
    9/9/2024$90.00Neutral
    JP Morgan
    Lantheus Holdings Inc.
    $LNTH
    9/3/2024$175.00Buy
    Redburn Atlantic
    More analyst ratings

    $GEHC
    $LNTH
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more
    • GE HealthCare upgraded by UBS with a new price target

      UBS upgraded GE HealthCare from Sell to Neutral and set a new price target of $73.00

      5/5/25 8:34:55 AM ET
      $GEHC
      Medical Electronics
      Health Care
    • GE HealthCare upgraded by Goldman with a new price target

      Goldman upgraded GE HealthCare from Neutral to Buy and set a new price target of $100.00 from $85.00 previously

      3/11/25 7:35:30 AM ET
      $GEHC
      Medical Electronics
      Health Care
    • GE HealthCare upgraded by Jefferies with a new price target

      Jefferies upgraded GE HealthCare from Hold to Buy and set a new price target of $103.00 from $95.00 previously

      1/8/25 7:50:38 AM ET
      $GEHC
      Medical Electronics
      Health Care

    $GEHC
    $LNTH
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • Jimenez Frank R bought $100,624 worth of shares (1,315 units at $76.52), increasing direct ownership by 2% to 75,796 units (SEC Form 4)

      4 - GE HealthCare Technologies Inc. (0001932393) (Issuer)

      5/2/24 6:00:38 AM ET
      $GEHC
      Medical Electronics
      Health Care
    • Lantheus Alpha Therapy, Llc bought $57,409,487 worth of shares (60,431,039 units at $0.95) (SEC Form 4)

      4 - Lantheus Holdings, Inc. (0001521036) (Reporting)

      3/8/24 11:24:53 AM ET
      $LNTH
      Biotechnology: In Vitro & In Vivo Diagnostic Substances
      Health Care

    $GEHC
    $LNTH
    Leadership Updates

    Live Leadership Updates

    See more
    • Lantheus Completes Acquisition of Life Molecular Imaging and Appoints Dr. Ludger Dinkelborg as Head of R&D

      BEDFORD, Mass., July 22, 2025 (GLOBE NEWSWIRE) -- Lantheus Holdings, Inc. ("Lantheus" or the "Company") (NASDAQ:LNTH), today announced the successful completion of its previously disclosed acquisition of Life Molecular Imaging Ltd. ("Life Molecular"), a subsidiary of Life Healthcare Group Holdings Ltd ("Life Healthcare"). As part of the acquisition, Ludger Dinkelborg, PhD, formerly CEO and Managing Director of Life Molecular Imaging, has been appointed Head of Research and Development at Lantheus effective August 1, 2025. "We are thrilled to welcome Dr. Dinkelborg and the entire Life Molecular team to Lantheus," said Brian Markison, CEO of Lantheus. "Ludger's proven leadership, scientific

      7/22/25 7:00:00 AM ET
      $LNTH
      Biotechnology: In Vitro & In Vivo Diagnostic Substances
      Health Care
    • PharmaLogic Announces Appointment of Etienne Montagut as President and Chief Executive Officer

      BOCA RATON, Fla., June 2, 2025 /PRNewswire/ -- PharmaLogic Holdings Corp. ("PharmaLogic" or "the Company"), a leading contract development and manufacturing organization (CDMO) specialized in radiopharmaceuticals, today announces the Company has appointed Etienne Montagut, currently serving as President, to the position of President and Chief Executive Officer, effective as of 1 June 2025. Mr. Montagut brings over 25 years of senior leadership experience in the pharmaceutical sector, with a solid track record of driving growth and executing strategic transformation across glob

      6/2/25 8:00:00 AM ET
      $GEHC
      $LNTH
      Medical Electronics
      Health Care
      Biotechnology: In Vitro & In Vivo Diagnostic Substances
    • GE HealthCare names Jeannette Bankes president and CEO, Patient Care Solutions

      GE HealthCare (NASDAQ:GEHC), a leading global healthcare solutions provider, announced the appointment of Jeannette Bankes as president and CEO, Patient Care Solutions, effective May 1, 2025. Peter Arduini, president and CEO, GE HealthCare, said, "Jeannette is a proven leader who has diverse and deep experience at publicly traded companies in the healthcare industry. We proudly welcome her to the company and are confident that she has the expertise to move Patient Care Solutions forward and deliver on our precision care strategy." Bankes brings with her three decades of global experience including product management, marketing, sales, regulatory, medical affairs, and operations and manufa

      4/9/25 9:00:00 AM ET
      $GEHC
      Medical Electronics
      Health Care

    $GEHC
    $LNTH
    SEC Filings

    See more
    • GE HealthCare Technologies Inc. filed SEC Form 8-K: Leadership Update

      8-K - GE HealthCare Technologies Inc. (0001932393) (Filer)

      7/24/25 4:33:29 PM ET
      $GEHC
      Medical Electronics
      Health Care
    • SEC Form 8-K filed by Lantheus Holdings Inc.

      8-K - Lantheus Holdings, Inc. (0001521036) (Filer)

      7/22/25 7:31:48 AM ET
      $LNTH
      Biotechnology: In Vitro & In Vivo Diagnostic Substances
      Health Care
    • GE HealthCare Technologies Inc. filed SEC Form 8-K: Other Events, Financial Statements and Exhibits

      8-K - GE HealthCare Technologies Inc. (0001932393) (Filer)

      6/9/25 4:07:02 PM ET
      $GEHC
      Medical Electronics
      Health Care

    $GEHC
    $LNTH
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • GE HealthCare launches new advanced digital X-ray system to enable access and increase efficiency in high throughput settings

      Definium™ Pace Select ET, a new floor-mounted digital X-ray system, enables access to affordable, high-quality medical imaging technology while easing workflow burdens in high-volume environments This new X-ray system, designed to act as a personal assistant for technologists, provides automation of in-room workflows and motorization of manual, repetitive tasks to increase throughput and reduce technologist learning curve GE HealthCare (NASDAQ:GEHC), today announced commercial availability of an advanced floor-mounted digital X-ray system, Definium™ Pace Select ET1, designed to deliver high-image quality and optimize efficiency in highly demanding environments while enhancing access

      7/24/25 12:30:00 PM ET
      $GEHC
      Medical Electronics
      Health Care
    • Lantheus to Host Second Quarter 2025 Earnings Conference Call and Webcast on August 6, 2025, at 8:00 a.m. Eastern Time

      BEDFORD, Mass., July 23, 2025 (GLOBE NEWSWIRE) -- Lantheus Holdings, Inc. (the "Company") (NASDAQ:LNTH) today announced that it will host a conference call and webcast at 8:00 a.m. ET on Wednesday, August 6, 2025, to discuss its financial results and provide a business update for the second quarter of 2025. To access the conference call or webcast, participants should register online at https://investor.lantheus.com/news-events/calendar-of-events. To avoid delays, we encourage participants to register fifteen minutes ahead of the scheduled start time. A replay will be available approximately two hours after completion of the webcast and will be archived on the same web page for at least

      7/23/25 8:00:00 AM ET
      $LNTH
      Biotechnology: In Vitro & In Vivo Diagnostic Substances
      Health Care
    • GE HealthCare drives growth with investment in AI-enabled medical devices and tops FDA's list of AI authorizations for 4th Year with 100

      Increased R&D investments to integrate AI on devices across disease states designed to boost productivity, efficiency, and diagnostic confidence for healthcare professionals, and drive the company's long-term growth Milestone advances GE HealthCare's goal of attaining more than 200 authorizations by 2028 GE HealthCare (NASDAQ:GEHC) has topped a U.S. Food and Drug Administration (FDA) list of AI-enabled medical device authorizations for the fourth year in a row with 100 listed authorizations to date in the U.S. This milestone reflects GE HealthCare's continued research and development (R&D) investment and focus on developing AI solutions to advance precision care by enhancing medica

      7/23/25 8:00:00 AM ET
      $GEHC
      Medical Electronics
      Health Care

    $GEHC
    $LNTH
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • President Blanchfield Paul covered exercise/tax liability with 518 shares, decreasing direct ownership by 0.46% to 111,274 units (SEC Form 4)

      4 - Lantheus Holdings, Inc. (0001521036) (Issuer)

      7/17/25 4:30:23 PM ET
      $LNTH
      Biotechnology: In Vitro & In Vivo Diagnostic Substances
      Health Care
    • Officer Niedzwiecki Daniel sold $472,440 worth of shares (6,000 units at $78.74), decreasing direct ownership by 6% to 87,057 units (SEC Form 4)

      4 - Lantheus Holdings, Inc. (0001521036) (Issuer)

      6/17/25 4:31:48 PM ET
      $LNTH
      Biotechnology: In Vitro & In Vivo Diagnostic Substances
      Health Care
    • Director Mchugh Julie sold $423,771 worth of shares (5,192 units at $81.62), decreasing direct ownership by 17% to 25,962 units (SEC Form 4)

      4 - Lantheus Holdings, Inc. (0001521036) (Issuer)

      6/11/25 4:33:01 PM ET
      $LNTH
      Biotechnology: In Vitro & In Vivo Diagnostic Substances
      Health Care

    $GEHC
    $LNTH
    Financials

    Live finance-specific insights

    See more
    • Lantheus to Host Second Quarter 2025 Earnings Conference Call and Webcast on August 6, 2025, at 8:00 a.m. Eastern Time

      BEDFORD, Mass., July 23, 2025 (GLOBE NEWSWIRE) -- Lantheus Holdings, Inc. (the "Company") (NASDAQ:LNTH) today announced that it will host a conference call and webcast at 8:00 a.m. ET on Wednesday, August 6, 2025, to discuss its financial results and provide a business update for the second quarter of 2025. To access the conference call or webcast, participants should register online at https://investor.lantheus.com/news-events/calendar-of-events. To avoid delays, we encourage participants to register fifteen minutes ahead of the scheduled start time. A replay will be available approximately two hours after completion of the webcast and will be archived on the same web page for at least

      7/23/25 8:00:00 AM ET
      $LNTH
      Biotechnology: In Vitro & In Vivo Diagnostic Substances
      Health Care
    • GE HealthCare to announce second quarter 2025 results on July 30, 2025

      GE HealthCare (NASDAQ:GEHC) will announce its second quarter 2025 financial results before the market opens on Wednesday, July 30, 2025. The GE HealthCare management team will also host a conference call and webcast at 8:30 a.m. Eastern Time / 7:30 a.m. Central Time on that same day, which will be a live webcast and accessible at https://investor.gehealthcare.com/news-events/events. The earnings release, accompanying financial information, and webcast replay also will be posted at the same link on the GE HealthCare Investor Relations website. About GE HealthCare Technologies Inc. GE HealthCare is a trusted partner and leading global healthcare solutions provider, innovating medical techno

      7/7/25 8:00:00 AM ET
      $GEHC
      Medical Electronics
      Health Care
    • GE HealthCare announces cash dividend for second quarter of 2025

      The Board of Directors of GE HealthCare Technologies Inc. (NASDAQ:GEHC) today declared a cash dividend of $0.035 per share of Common Stock for the second quarter of 2025 payable on August 15, 2025 to all shareholders of record as of July 25, 2025. About GE HealthCare Technologies Inc. GE HealthCare is a trusted partner and leading global healthcare solutions provider, innovating medical technology, pharmaceutical diagnostics, and integrated, cloud-first AI-enabled solutions, services and data analytics. We aim to make hospitals and health systems more efficient, clinicians more effective, therapies more precise, and patients healthier and happier. Serving patients and providers for more

      7/1/25 8:34:00 AM ET
      $GEHC
      Medical Electronics
      Health Care

    $GEHC
    $LNTH
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • SEC Form SC 13G filed by Lantheus Holdings Inc.

      SC 13G - Lantheus Holdings, Inc. (0001521036) (Subject)

      11/14/24 8:21:14 PM ET
      $LNTH
      Biotechnology: In Vitro & In Vivo Diagnostic Substances
      Health Care
    • Amendment: SEC Form SC 13G/A filed by Lantheus Holdings Inc.

      SC 13G/A - Lantheus Holdings, Inc. (0001521036) (Subject)

      11/14/24 3:29:28 PM ET
      $LNTH
      Biotechnology: In Vitro & In Vivo Diagnostic Substances
      Health Care
    • Amendment: SEC Form SC 13G/A filed by GE HealthCare Technologies Inc.

      SC 13G/A - GE HealthCare Technologies Inc. (0001932393) (Subject)

      11/12/24 12:53:28 PM ET
      $GEHC
      Medical Electronics
      Health Care